Pfizer Beats Revenue Estimates, Merck Misses Forecasts, PepsiCo Faces Consumer Pushback

Pfizer's Fourth Quarter Performance

• 📈 Pfizer reported fourth quarter sales of $17.5 billion, beating estimates.
• 💊 The company is maintaining its full-year guidance for earnings per share and revenue, with $5 billion expected from COVID-19 products.
• 💡 Pfizer also released positive study results on its ultra-long-lasting GLP1 weight loss drug, which met primary endpoints and is moving to monthly dosing, potentially increasing market accessibility.

Merck's Financial Outlook and Challenges

• 📉 Despite a fourth quarter beat, Merck shares are down due to disappointing 2026 forecasts.
• 💰 The company projects $67 billion in sales for the year, below analyst expectations.
• ⚠️ A significant factor is the decline in Chinese demand for its HPV treatment Gardasil, its second-largest product, with no shipments to China assumed in forward guidance.
• 💉 Merck is also facing challenges with Gardasil in the US, as health officials recommend fewer doses.

PepsiCo's Earnings and Strategic Adjustments

• 🥤 PepsiCo reported better-than-expected fourth quarter profit, driven by strong international demand.
• 💰 The company announced a $10 billion share buyback program through 2030.
• 📉 However, the stock is down due to a 1% contraction in US foods sales, the only region to see a decline.
• 🛒 PepsiCo is planning price cuts in response to consumer pushback and a shift towards cheaper off-brand products, a strategy discussed with activist investor Elliot.

Palantir's Strong Performance

• 🚀 Data and analytics company Palantir beat fourth quarter estimates for both revenue and profit.
• 📈 Significant growth was seen in government revenue (up 60%) and commercial sales (up 80%) year-over-year.
• 🎯 Palantir is predicting 61% sales growth for the current year, exceeding estimates, and its earnings guidance is also above expectations.
• 💥 The stock is up 11% in pre-market trading, a notable bounce after being down 29% prior to the earnings report.